Company intelligence / Profile preview

Apthera

Scottsdale, Arizona, United States

Ownership: Private
Development stage: Other

Overview

Apthera developed NeuVax, a peptide-based immunotherapy designed for adjuvant treatment of low-to-intermediate HER2+ breast cancer not eligible for Herceptin. NeuVax showed positive results in Phase 2 for disease free survival and was cleared to enter a pivotal Phase 3 trial under FDA Special Protocol Assessment before Apthera was acquired by RXi Pharmaceuticals in 2011[1][4].

Therapeutic areas: Oncology
Modalities: PeptidesBiologic
Industry: Biotech

Partnerships

TGen Drug Development Services (TD2)[3]

Beyond the preview

Go deeper on Apthera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apthera.

Explore the full profile